New Analysis Suggests Long-Term Effectiveness for Wegovy Users
- 7 days ago
New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .
NBC reports that patients taking
Novo Nordisk's obesity treatment maintain
an average of 10% weight loss over four years.
The news potentially boosts the
drugmaker's push for Wegovy to be
covered by insurers and governments. .
The company submitted long-term
findings at the European Congress
on Obesity in Venice, Italy. .
This is the longest study
we’ve conducted so far of
semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.
We see that once the majority
of the weight loss is accrued,
you don’t go back and start
to increase in weight
if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.
According to another analysis published by
the drugmaker, approximately 17% of trial participants stopped using the treatment
due to side effects like nausea. .
The costly treatment ranges from $200
to nearly $2,000 per month in the ten
countries where the drug is available.
NBC reports that Novo Nordisk was the
first drugmaker to market GLP-1 agonists,
originally developed as a diabetes treatment,
to address record high obesity rates.
NBC reports that Novo Nordisk was the
first drugmaker to market GLP-1 agonists,
originally developed as a diabetes treatment,
to address record high obesity rates.
Rival Eli Lilly launched its drug
Zepbound in the United States
in December of 2023. .
Neither drugmaker has managed
to produce enough of the
treatment to meet surging demand
NBC reports that patients taking
Novo Nordisk's obesity treatment maintain
an average of 10% weight loss over four years.
The news potentially boosts the
drugmaker's push for Wegovy to be
covered by insurers and governments. .
The company submitted long-term
findings at the European Congress
on Obesity in Venice, Italy. .
This is the longest study
we’ve conducted so far of
semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.
We see that once the majority
of the weight loss is accrued,
you don’t go back and start
to increase in weight
if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.
According to another analysis published by
the drugmaker, approximately 17% of trial participants stopped using the treatment
due to side effects like nausea. .
The costly treatment ranges from $200
to nearly $2,000 per month in the ten
countries where the drug is available.
NBC reports that Novo Nordisk was the
first drugmaker to market GLP-1 agonists,
originally developed as a diabetes treatment,
to address record high obesity rates.
NBC reports that Novo Nordisk was the
first drugmaker to market GLP-1 agonists,
originally developed as a diabetes treatment,
to address record high obesity rates.
Rival Eli Lilly launched its drug
Zepbound in the United States
in December of 2023. .
Neither drugmaker has managed
to produce enough of the
treatment to meet surging demand